Invitae Corporation

Invitae Corporation (NVTA)

$1.18

-0.02

(-1.67%)

Market is closed - opens 7 PM, 12 Jun 2023

Insights on Invitae Corporation

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 136.62M → 117.35M (in $), with an average decrease of 4.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -99.81M → -192.18M (in $), with an average decrease of 92.5% per quarter

  • Vs IDXX

    In the last 1 year, Idexx Laboratories, Inc. has given 30.4% return, outperforming this stock by 81.6%

  • Vs TMO

    In the last 3 years, Thermo Fisher Scientific, Inc. has given 40.1% return, outperforming this stock by 133.4%

Performance

  • $1.17
    $1.30
    $1.18
    downward going graph

    0.85%

    Downside

    Day's Volatility :10.0%

    Upside

    9.23%

    downward going graph
  • $1.02
    $9.00
    $1.18
    downward going graph

    13.56%

    Downside

    52 Weeks Volatility :88.67%

    Upside

    86.89%

    downward going graph

Returns

PeriodInvitae CorporationSector (Health Care)Index (Russel 2000)
3 Months
-16.31%
5.1%
-0.2%
6 Months
-49.14%
-5.5%
-1.5%
1 Year
-51.24%
3.9%
-1.7%
3 Years
-93.31%
27.0%
20.6%

Highlights

Market Capitalization
328.6M
Book Value
- $0.14
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-12.73
PEG Ratio
-0.51
Wall Street Target Price
2.03
Profit Margin
0.0%
Operating Margin TTM
-122.32%
Return On Assets TTM
-12.07%
Return On Equity TTM
-222.04%
Revenue TTM
510.0M
Revenue Per Share TTM
2.12
Quarterly Revenue Growth YOY
-5.1%
Gross Profit TTM
99.0M
EBITDA
-480.0M
Diluted Eps TTM
-12.73
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.41
EPS Estimate Next Year
-1.17
EPS Estimate Current Quarter
-0.39
EPS Estimate Next Quarter
-0.36

Analyst Recommendation

Hold
    0
    0%Buy
    56%Hold
    43%Sell
Based on 16 Wall street analysts offering stock ratings for Invitae Corporation(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
9
9
9
Sell
7
7
7

Analyst Forecast

What analysts predicted

Upside of 72.03%

Current $1.18
Target $2.03

Company Financials

FY17Y/Y Change
Revenue
68.2M
↑ 172.36%
Net Income
-123.4M
↑ 23.06%
Net Profit Margin
-180.85%
↑ 219.41%
FY18Y/Y Change
Revenue
147.7M
↑ 116.5%
Net Income
-129.4M
↑ 4.84%
Net Profit Margin
-87.58%
↑ 93.27%
FY19Y/Y Change
Revenue
216.8M
↑ 46.8%
Net Income
-242.0M
↑ 87.06%
Net Profit Margin
-111.6%
↓ 24.02%
FY20Y/Y Change
Revenue
279.6M
↑ 28.95%
Net Income
-602.2M
↑ 148.87%
Net Profit Margin
-215.37%
↓ 103.77%
FY21Y/Y Change
Revenue
460.4M
↑ 64.68%
Net Income
-379.0M
↓ 37.06%
Net Profit Margin
-82.31%
↑ 133.06%
FY22Y/Y Change
Revenue
516.3M
↑ 12.13%
Net Income
-3.1B
↑ 719.59%
Net Profit Margin
-601.64%
↓ 519.33%
Q4 FY21Q/Q Change
Revenue
126.1M
↑ 10.25%
Net Income
-205.1M
↑ 3.51%
Net Profit Margin
-162.64%
↑ 10.6%
Q1 FY22Q/Q Change
Revenue
123.7M
↓ 1.93%
Net Income
-181.9M
↓ 11.34%
Net Profit Margin
-147.03%
↑ 15.61%
Q2 FY22Q/Q Change
Revenue
136.6M
↑ 10.45%
Net Income
-2.5B
↑ 1287.59%
Net Profit Margin
-1.8K%
↓ 1700.01%
Q3 FY22Q/Q Change
Revenue
133.5M
↓ 2.26%
Net Income
-301.2M
↓ 88.07%
Net Profit Margin
-225.52%
↑ 1621.52%
Q4 FY22Q/Q Change
Revenue
122.5M
↓ 8.3%
Net Income
-99.8M
↓ 66.86%
Net Profit Margin
-81.51%
↑ 144.01%
Q1 FY23Q/Q Change
Revenue
117.4M
↓ 4.16%
Net Income
-192.2M
↑ 92.54%
Net Profit Margin
-163.76%
↓ 82.25%
FY17Y/Y Change
Total Assets
211.1M
↑ 61.56%
Total Liabilities
89.3M
↑ 182.75%
FY18Y/Y Change
Total Assets
283.0M
↑ 34.05%
Total Liabilities
121.1M
↑ 35.66%
FY19Y/Y Change
Total Assets
781.6M
↑ 176.22%
Total Liabilities
402.0M
↑ 231.87%
FY20Y/Y Change
Total Assets
3.4B
↑ 338.9%
Total Liabilities
1.5B
↑ 261.77%
FY21Y/Y Change
Total Assets
4.9B
↑ 43.41%
Total Liabilities
1.9B
↑ 33.49%
FY22Y/Y Change
Total Assets
2.0B
↓ 60.28%
Total Liabilities
1.9B
↓ 4.58%
Q4 FY21Q/Q Change
Total Assets
4.9B
↓ 2.99%
Total Liabilities
1.9B
↓ 1.18%
Q1 FY22Q/Q Change
Total Assets
4.8B
↓ 3.09%
Total Liabilities
1.9B
↓ 0.89%
Q2 FY22Q/Q Change
Total Assets
2.3B
↓ 51.96%
Total Liabilities
1.9B
↓ 1.0%
Q3 FY22Q/Q Change
Total Assets
2.0B
↓ 11.54%
Total Liabilities
1.9B
↓ 1.95%
Q4 FY22Q/Q Change
Total Assets
2.0B
↓ 3.56%
Total Liabilities
1.9B
↓ 0.81%
Q1 FY23Q/Q Change
Total Assets
1.7B
↓ 13.43%
Total Liabilities
1.7B
↓ 6.69%
FY17Y/Y Change
Operating Cash Flow
-98.0M
↑ 28.39%
Investing Cash Flow
-37.0M
↓ 328.18%
Financing Cash Flow
80.9M
↑ 50.57%
FY18Y/Y Change
Operating Cash Flow
-92.2M
↓ 5.88%
Investing Cash Flow
35.8M
↓ 196.81%
Financing Cash Flow
157.2M
↑ 94.32%
FY19Y/Y Change
Operating Cash Flow
-145.1M
↑ 57.29%
Investing Cash Flow
-280.3M
↓ 883.58%
Financing Cash Flow
464.8M
↑ 195.75%
FY20Y/Y Change
Operating Cash Flow
-298.5M
↑ 105.79%
Investing Cash Flow
-400.6M
↑ 42.91%
Financing Cash Flow
673.0M
↑ 44.8%
FY21Y/Y Change
Operating Cash Flow
-559.8M
↑ 87.54%
Investing Cash Flow
-204.1M
↓ 49.05%
Financing Cash Flow
1.6B
↑ 132.68%
Q4 FY21Q/Q Change
Operating Cash Flow
-175.9M
↑ 6.58%
Investing Cash Flow
170.5M
↓ 938.92%
Financing Cash Flow
7.0M
↓ 1056.6%
Q1 FY22Q/Q Change
Operating Cash Flow
-147.5M
↓ 16.13%
Investing Cash Flow
-449.5M
↓ 363.61%
Financing Cash Flow
-920.0K
↓ 113.08%
Q2 FY22Q/Q Change
Operating Cash Flow
-134.7M
↓ 8.71%
Investing Cash Flow
109.0M
↓ 124.24%
Financing Cash Flow
3.8M
↓ 509.78%
Q3 FY22Q/Q Change
Operating Cash Flow
-128.7M
↓ 4.45%
Investing Cash Flow
43.8M
↓ 59.81%
Financing Cash Flow
-1.7M
↓ 144.85%
Q1 FY23Q/Q Change
Operating Cash Flow
-34.4M
↓ 58.07%
Investing Cash Flow
73.9M
-
Financing Cash Flow
-135.8M
↓ 22765.78%

Technicals Summary

Sell

Neutral

Buy

Invitae Corporation is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Invitae Corporation
Invitae Corporation
-20.81%
-49.14%
-51.24%
-93.31%
-85.03%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-7.04%
6.58%
30.38%
40.09%
103.99%
Agilent Technologies Inc.
Agilent Technologies Inc.
-9.58%
-25.46%
-3.96%
28.93%
75.09%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-2.87%
-8.71%
-1.65%
46.88%
138.42%
Danaher Corp.
Danaher Corp.
0.83%
-13.94%
-6.41%
36.3%
127.98%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
9.84%
-3.07%
-0.38%
40.36%
98.32%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Invitae Corporation
Invitae Corporation
NA
NA
-0.51
-1.41
-2.22
-0.12
0.0
-0.14
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
55.24
55.24
7.21
9.69
0.94
0.22
0.0
10.13
Agilent Technologies Inc.
Agilent Technologies Inc.
26.6
26.6
2.36
5.61
24.78
0.1
0.01
19.58
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
28.89
28.89
4.28
23.71
14.48
0.05
0.0
109.55
Danaher Corp.
Danaher Corp.
25.34
25.34
3.24
8.79
0.14
0.06
0.0
68.31
Iqvia Holdings Inc.
Iqvia Holdings Inc.
35.29
35.29
1.48
10.42
17.8
0.05
0.0
31.98
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Invitae Corporation
Invitae Corporation
Hold
$328.6M
-85.03%
NA
0.0%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$37.6B
103.99%
55.24
20.38%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$34.4B
75.09%
26.6
19.19%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$200.9B
138.42%
28.89
13.75%
Danaher Corp.
Danaher Corp.
Buy
$173.7B
127.98%
25.34
22.4%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$38.3B
98.32%
35.29
7.28%

Institutional Holdings

  • ARK Investment Management LLC

    12.02%
  • BlackRock Inc

    8.35%
  • Vanguard Group Inc

    7.03%
  • Nikko Asset Management Americas Inc

    6.62%
  • Sumitomo Mitsui Trust Holdings Inc

    6.51%
  • Deerfield Management Co

    3.56%

Corporate Announcements

  • Invitae Corporation Earnings

    Invitae Corporation’s price-to-earnings ratio stands at None

    Read More

Company Information

invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people. specializing in genetic diagnostics for hereditary disorders, invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today. choose from our curated panels or design your own test for the same low price. today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. together we can improve healthcare for billions of people.

Organization
Invitae Corporation
Employees
1700
CEO
Mr. Kenneth D. Knight
Industry
Health Services

FAQs